Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
Rhea-AI Summary
Aligos Therapeutics (Nasdaq: ALGS) provided a Phase 2 B-SUPREME study update for pevifoscorvir sodium in chronic HBV. The study has 144 subjects enrolled worldwide and remains on track to complete enrollment with topline data expected in 2027. The first protocol‑defined interim analysis (≈36 HBeAg‑ participants completing 12 weeks) is expected in 1H 2026; the second interim (≈55 HBeAg+ participants completing 24 weeks) is expected in 2H 2026. The company will remain blinded and rely on the Data Safety Monitoring Board for protocol assessments, including potential sample size re‑estimation. The company also announced the resignation of its EVP/CMO and has initiated a formal search for a successor.
Positive
- Study enrollment of 144 subjects worldwide
- First interim milestone met: 36 HBeAg- completed 12 weeks
- Topline data expected in 2027
Negative
- EVP/CMO resignation may disrupt clinical leadership
- Interim analyses allow for sample size re-estimation, adding uncertainty
News Market Reaction
On the day this news was published, ALGS declined 0.12%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.8% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $66K from the company's valuation, bringing the market cap to $55M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ALGS was up 0.88% while close peers showed mixed moves (e.g., BYSI +0.59%, IGMS -2.31%, ACET -2.71%, CVM +1.74%, ENTX -1.87%), pointing to stock-specific drivers rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Leadership appointment | Positive | +6.1% | New Chief Commercial Officer appointed to build global commercial capabilities. |
| Dec 12 | Equity inducement awards | Neutral | +15.5% | Stock option inducement grants to new hires under 2024 Inducement Plan. |
| Dec 11 | Scientific data update | Positive | +1.6% | Positive HEP‑DART 2025 data for HBV program and obesity candidate ALG‑055009. |
| Nov 14 | Equity inducement awards | Neutral | +9.7% | Additional stock option inducement awards to newly hired employees. |
| Nov 10 | Clinical data presentation | Positive | -2.6% | Positive Phase 1 and preclinical data for pevifoscorvir sodium and ALG‑001075. |
Shares have often reacted strongly to routine equity/inducement announcements and have shown mixed follow-through on positive clinical or scientific updates.
Over the past six months, Aligos has combined clinical progress in chronic HBV with organizational and capital-structure developments. Positive liver-related data and presentations in Nov–Dec 2025 for pevifoscorvir sodium and ALG‑001075 supported the B‑SUPREME program. Routine inducement grants in Nov and Dec 2025 still coincided with sizable price moves. In Jan 2026, the company strengthened its commercial leadership as it plans for potential late-stage development. Today’s B‑SUPREME progress update and CMO change fit into this transition toward more advanced clinical stages.
Market Pulse Summary
This announcement detailed steady execution in the Phase 2 B‑SUPREME trial, with 144 subjects enrolled and protocol-defined interim analyses planned for both HBeAg- and HBeAg+ cohorts in 2026, ahead of topline data in 2027. The company remains blinded, relying on an independent Data Safety Monitoring Board for interim insights. Alongside this, the Chief Medical Officer resigned and a search for a successor began. Investors may watch enrollment completion, interim readouts, and leadership continuity as key next checkpoints.
Key Terms
phase 2 medical
chronic hepatitis b virus (hbv) medical
hbeag- medical
hbeag+ medical
data safety monitoring board medical
fda regulatory
AI-generated analysis. Not financial advice.
Interim analyses on track for the first and second half of 2026
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus (HBV) infection.
“2026 is an important year for Aligos as we continue to make progress with the Phase 2 B-SUPREME study with 144 subjects currently enrolled across the world,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO. “We look forward to our interim analyses, which will contain directional insights on how the study is tracking. The study remains on track to complete enrollment, with topline data expected in 2027. We believe pevifoscorvir sodium is poised for success in this study and look forward to sharing more details later this year.”
Planned Interim Analyses
The first protocol defined interim analysis includes approximately
A second protocol defined interim analysis is planned when approximately
To preserve study integrity and comply with FDA regulatory requirements, the company will remain blinded to subject-level data and will receive insights from the Data Safety Monitoring Board on protocol-specified assessments, including the potential for sample size re-estimation at each interim analysis.
Leadership Change
Hardean Achneck, MD resigned from his position as Executive Vice President, Chief Medical Officer. The company thanks him for his contributions and wishes him success in his future endeavors. A formal search has commenced to identify his successor.
About B-SUPREME
The Phase 2 B-SUPREME study (NCT06963710) is a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of ALG-000184 monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated HBeAg+ and HBeAg- adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg+ part is HBV DNA <LLOQ (10 IU/mL, target detected [TD] or target not detected [TND]) and the primary endpoint in the HBeAg- part is HBV DNA <LLOQ (10 IU/mL, target not detected [TND]). The study will also evaluate the safety, pharmacokinetics, and other secondary and exploratory biomarkers, including reductions in HBV antigens and other markers of HBV infection.
About pevifoscorvir sodium
Pevifoscorvir sodium (formerly known as ALG-000184) was derived from initial IP licensed from the laboratory of Dr. Raymond Schinazi at Emory University, which was further optimized by Aligos. Pevifoscorvir sodium is a potent potential best/first-in-class oral small molecule capsid assembly modulator (CAM-E) being developed for chronic hepatitis B virus (HBV) infection. Phase 1 studies have demonstrated after single and multiple daily doses that pevifoscorvir sodium was well-tolerated by study participants, with no safety signals observed, and demonstrated linear PK and excellent antiviral activity. In longer term Phase 1 studies, pevifoscorvir sodium 300mg QD x ≤96 weeks monotherapy has demonstrated sustained reductions in HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg. Pevifoscorvir sodium has a regulatory path, as acknowledged by the FDA, EMA, and NMPA (China), for subsequent studies utilizing the chronic suppressive pathway.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ potential success in meeting research and development milestones, the outcome of our clinical trials, the potential success in our regulatory path for pevifoscrovir sodium, and the timing of announcements and updates relating to our clinical trial progress and regulatory filings. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com
FAQ
How many subjects are enrolled in Aligos B-SUPREME Phase 2 as of Jan 21, 2026 (ALGS)?
When is the first interim analysis for ALGS B-SUPREME expected?
When will Aligos report topline B-SUPREME results for ALGS?
What triggers the second interim analysis in the ALGS B-SUPREME study?
Will Aligos be unblinded for the B-SUPREME interim analyses (ALGS)?
What leadership change did Aligos announce on Jan 21, 2026 (ALGS)?
